logo
Plus   Neg
Share
Email
Comment

KineMed And Pfizer Extend Collaboration On Type II Diabetes - Quick Facts

KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.

KineMed stated that the collaboration employs its novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials," said Marc Hellerstein, President, Chief Science Officer and Co-founder at KineMed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
HP Inc. (HPQ), the PC and printer business of the former Hewlett-Packard Co., on Thursday reported a profit for the first quarter that increased from last year and trumped analysts' expectations driven largely by a higher-than-expected revenues. The PC giant detailed a second-quarter and full year... Hormel Foods Corp. (HRL) reported a profit for the first quarter of fiscal 2018 that increased 28.9 percent from the prior year. Total net sales grew 2.2 percent from last year. Earnings per share topped analysts' expectations, while quarterly revenues missed their estimates. The company raised annual earnings per share guidance due to U.S. tax reform, while it maintained annual net sales outlook. Shares of Deutsche Telekom AG were losing around 3 percent in the morning trading in Germany after the telecom giant reported Thursday a decline in fourth-quarter EBITDA, a key earnings metric, with weak revenues. However, the company recorded a net profit, compared to loss last year on positive US tax effect. Deutsche Telekom lifted its dividend and said it expects higher earnings in 2018.
comments powered by Disqus
Follow RTT